Clinical Trials Directory

Trials / Approved For Marketing

Approved For MarketingNCT00650026

Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis

Multicenter Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis

Status
Approved For Marketing
Phase
—
Study type
Expanded Access
Enrollment
—
Sponsor
Abbott · Industry
Sex
All
Age
18 Years
Healthy volunteers
—

Summary

Multicenter Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Active Rheumatoid Arthritis

Conditions

Interventions

TypeNameDescription
BIOLOGICALadalimumab40 mg adalimumab every other week

Timeline

First posted
2008-04-01
Last updated
2008-04-14

Source: ClinicalTrials.gov record NCT00650026. Inclusion in this directory is not an endorsement.

Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid A (NCT00650026) · Clinical Trials Directory